Iovance Biotherapeutics (IOVA) Non-Current Assets (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Non-Current Assets of $459.2 million for Q1 2026, up 1.12% year-over-year from $454.1 million in Q1 2025, and down 2.41% quarter-over-quarter from $470.5 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Non-Current Assets (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Non-Current Assets for 17 consecutive years, with $459.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 1.12% year-over-year to $459.2 million; the TTM figure through Mar 2026 stood at $1.9 billion (up 1.4% YoY), while the FY2025 annual figure was $470.5 million, up 3.77% from the prior year.
- Non-Current Assets fell to $459.2 million in Q1 2026 per IOVA's latest filing, from $470.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $484.9 million in Q2 2025 and bottomed at $176.0 million in Q3 2022.
- Historically, Non-Current Assets has averaged $376.4 million across 5 years, with a median of $459.2 million in 2026.
- Annual changes were most pronounced in 2022 — Non-Current Assets sank 31.37% — and 2023, when it soared 169.08%.
- Iovance Biotherapeutics' Non-Current Assets stood at $184.9 million in 2022, then soared by 155.59% to $472.5 million in 2023, then decreased by 4.04% to $453.4 million in 2024, then grew by 3.77% to $470.5 million in 2025, then fell by 2.41% to $459.2 million in 2026.
- Business Quant data shows IOVA's Non-Current Assets at $459.2 million in Q1 2026, $470.5 million in Q4 2025, and $475.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 451.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 451.27 Mn |
| Mar 31, 2026 | 459.16 Mn |
| Dec 31, 2025 | 470.48 Mn |
| Sep 30, 2025 | 475.86 Mn |
| Jun 30, 2025 | 484.94 Mn |
| Mar 31, 2025 | 454.09 Mn |
| Dec 31, 2024 | 453.41 Mn |
| Mar 31, 2024 | 484.30 Mn |
| Dec 31, 2023 | 472.50 Mn |
| Sep 30, 2023 | 469.73 Mn |
| Jun 30, 2023 | 482.42 Mn |
| Mar 31, 2023 | 186.99 Mn |
| Dec 31, 2022 | 184.87 Mn |
| Sep 30, 2022 | 176.04 Mn |
| Jun 30, 2022 | 179.29 Mn |
| Mar 31, 2022 | 211.28 Mn |
| Dec 31, 2021 | 269.38 Mn |
| Sep 30, 2021 | 245.80 Mn |
| Jun 30, 2021 | 186.15 Mn |
| Mar 31, 2021 | 145.36 Mn |